In vivo data highlights the specific tissue and cellular targeting capabilities of ReNeuron’s stem cell derived exosome drug delivery platform, CustomEXTM
In vivo data highlights the specific tissue and cellular targeting capabilities of ReNeuron’s stem cell derived exosome drug delivery platform, CustomEXTM
Creating a valuable and differentiated Exosome Delivery Platform
3 May 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces that the Company will be attending the International Society of Cell and Gene Therapy Annual Meeting (ISCT 2022) from the 4-7 May in San Francisco, California.
11 January 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem cell and Exosome Technologies, announces that Dr Randolph Corteling will re-join ReNeuron on 3 March 2022, heading up the Research team as Vice President of Research and will report directly into the CEO.
30 November 2021: ReNeuron Group plc (AIM: RENE), a UK based leader in Stem Cell and Exosome Technologies, announces its interim results for the six months ended 30 September 2021.
Significantly improved delivery of functional proteins to the brain demonstrated in vivo
Further collaborations underway to demonstrate the potential of ReNeuron’s proprietary exosome platform
Emerging data shows platform’s application to a range of novel therapeutics targeting the brain and other tissues
10 September 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of today’s Annual General Meeting (“AGM”).
To view the presentation of the preliminary results for the year ended 31 March 2020 please click here.
20 July 2020: ReNeuron Group plc (AIM: RENE.L), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its preliminary results for the year ended 31 March 2020.